Bio-Techne earnings date and guidance
MyStockButler's October 2026 analysis: Bio-Techne's next results are expected on November 4, 2026. The key thing to watch is repeated organic growth with stable product margins and stronger cash conversion.
What has Bio-Techne guided for the Wilson Wolf payment?
The Wilson Wolf deal began as a staged purchase, but its first contractual trigger has made the remaining ownership compulsory. The scheduled purchase falls on December 31, 2027, unless a second performance milestone brings it forward. The guided second-stage payment is therefore cash Bio-Techne must prepare to find, not an ordinary option it can simply abandon.
| Period guided | Low | High | Date given | |
|---|---|---|---|---|
| Second option payment | Fiscal 2027–2028 | 1,000,000 | 1,000,000 | Aug 24, 2026 |
What this means. The one million dollar payment is an estimate for an option and may not be the full amount because extra payments could be added.
Has Bio-Techne kept its capital-spending promises?
Capital additions came below guidance in all five years reviewed. For FY2026, the plan was approximately $42 million, while actual spending was $28.85 million. That preserves cash but may postpone useful capacity, and it says little about revenue or earnings performance.
| What management forecast | Checked | Above | Within | Below |
|---|---|---|---|---|
| Capital additions | 5 years | 0 | 0 | 5 |
What are Bio-Techne's last eight quarters of revenue and profit?
Reported revenue rose 1.3% year over year, and organic growth reached 3%. A held-for-sale business created a two-point headwind, while currency had no material effect. This was a welcome change after three quarters of year-over-year reported declines, but one positive comparison cannot establish a durable turn.
The adjusted figures are more restrained. Adjusted operating margin edged higher, but adjusted EPS slipped from $0.53 to $0.52. Free cash flow also fell, reflecting lower operating cash and higher capital spending. June looks like an improvement in demand, particularly in Diagnostics and Spatial Biology, not yet proof of a broad earnings recovery.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 321,191 | 311,415 | 295,877 | 286,555 | 316,964 | 316,181 | 297,031 | 289,458 |
| Gross margin | 65.8% | 66.9% | 64.6% | 65.6% | 62.7% | 67.9% | 65.3% | 63.2% |
| Operating income | 74,277 | 75,495 | 54,461 | 47,658 | -23,860 | 38,708 | 47,419 | 39,987 |
| Net income | 54,622 | 51,047 | 38,009 | 38,185 | -17,677 | 22,588 | 34,890 | 33,600 |
| EPS, diluted | 0.35 | 0.32 | 0.24 | 0.24 | -0.11 | 0.14 | 0.22 | 0.21 |
What should investors watch in Bio-Techne's next release?
The next convincing signal would be repeated organic growth accompanied by stable product margins and stronger cash conversion.